CYSLTR1 and acute respiratory distress syndrome: Leukotriene‐modifying agents, such as montelukast (a CysLTR1 antagonist) and zileuton (a 5‐lipoxygenase inhibitor), are approved for chronic inflammatory lung diseases, but their role in ARDS is unclear.